؉ cells isolated from peripheral blood (PB) of steady-state healthy volunteers (ssPB-CD34), and of patients or healthy volunteers after mobilization (mPB-CD34) were investigated. ssPB-CD34
Introduction
The presence of hematopoietic progenitors in the peripheral blood of mammals, albeit in very low numbers, has been known for a long time. [1] [2] [3] More recently, conditions have been described that lead to a significant increase in the number of circulating progenitors: during the recovery phase from chemotherapy-induced cytopenia (at least following the administration of certain cytotoxic drugs such as cyclophosphamide), or following administration of cytokines and hematopoietic growth factors, CFU-GM, LTC-IC and CD34 ϩ cell numbers in peripheral blood transiently increase. These observations provide the basis on which to develop clinical programs that use mobilized peripheral blood progenitor cells (mPBPC), rather than BM (reviewed in Ref. 4) . Most hematopoietic growth factors and cytokines induce mobilization of hematopoietic progenitor cells. This effect is not restricted to committed progenitors from the lineage on which the hematopoietic growth factor or cytokine is supposedly most active (eg G-CSF mobilize not only CFU-GM or CFU-G, but also BFU-E). Molecular and cellular mechanisms that underlie mobilization remain poorly understood, although adhesion molecules such as integrins are likely to play important roles. 5, 6 Furthermore, very little has been elucidated with respect to the influence of mobilization procedures on the function and reconstitution potential of hematopoietic progenitors.
These questions are important because circulating progenitor cells collected in cancer patients or in healthy donors, following mobilization, have been increasingly used in clinical programs during the last decade. 4 Following high-dose chemotherapy, the reinfusion of autologous peripheral blood cells in lieu of autologous BM cells results in a more rapid neutrophil and platelet recovery, presumably due to the higher numbers of infused progenitors; this contributes to a decrease in the use of medical resources. Allogeneic mobilized blood cells support the rapid reconstitution with complete chimerism in all lympho-myeloid lineages. [7] [8] [9] [10] In addition, mobilized peripheral blood cells have been used for stem cell-based therapies that require ex vivo manipulations, such as CD34 ϩ cell selection, ex vivo expansion and gene transfer. Besides the ease of collection, they initially appeared as optimal targets for retrovirus-mediated gene transfer, due to their cycling status, 11 a property that is necessary to ensure murine retrovirus integration into the host genome. 12 However, this early appreciation was recently reconsidered, with studies demonstrating that mobilized blood progenitors are actually low-cycling cells, 13, 14 and that they however rapidly enter cell cycle when stimulated with cytokines. 15, 16 Results of pre-clinical or clinical studies with genetically modified peripheral blood stem cells demonstrated that ex vivo retroviral gene transfer occurs. 17, 18 However, levels of reconstitution achieved by genetically modified PBPC tend to be lower than those obtained with cord blood or with fetal liver cells, [19] [20] [21] [22] [23] [24] indicating that progenitor cells isolated from different sources possess different biological properties.
These may include their ability to respond to different cytokines or cytokine combinations, and retain their hematopoietic repopulating ability, following ex vivo culture. 25 One recently published study demonstrated that human adult blood CD34
ϩ cells cultured for 8 days with a combination of five cytokines (KL, IL-1, IL-3, IL-6 and Epo) did not support autologous reconstitution in four patients who were myeloablated with regimens containing either busulfan or total body irradiation. 26 Mouse studies provided contradictory results, suggesting either the maintenance, [27] [28] [29] or the loss 30-33 of reconstitution potential, following ex vivo culture of progenitors isolated from different sources. A recent report in nonhuman primates also suggested that genetically marked peripheral blood cells may partially loose their ability to engraft myeloablated animals, following ex vivo expansion for 10-14 days. 34 Identification of optimal target cell populations for gene transfer and understanding of factors that regulate their behavior are therefore critical issues in facilitating higher levels of reconstitution by ex vivo manipulated progenitor cells.
The present study was designed to compare the phenotype and function of mPBPC and steady-state PBPC (ssPBPC), with an emphasis on the ability to maintain the reconstitution potential during ex vivo manipulation. Several aspects of the phenotype and function of mPBPC have already been described, [35] [36] [37] and compared with those of BM progenitors, [38] [39] [40] [41] [42] [43] or cord blood progenitors. 39, 44 The phenotype [45] [46] [47] and function [48] [49] [50] of rare circulating ssPBPC have also been studied. However, experiments to directly compare the phenotype and function of mPBPC and ssPBPC have rarely been conducted. 40, 51 In the present study, the hematopoietic reconstitution potentials of mPBPC and ssPBPC were investigated with the SCID-hu mouse model, 52, 53 in addition to flow cytometry analyses and in vitro studies. In a previous work, 22 we demonstrated that ex vivo manipulated primitive progenitors isolated from human fetal liver successfully reconstitute the full spectrum of human hematopoiesis in SCID-hu mice: B and T lymphoid cells, myeloid cells, primitive and mature clonogenic progenitor cells expressing a transduced nls-LacZ gene were recovered from human hematopoietic organs implanted in SCID-hu mice. Using the same protocol, we compared in vivo hematopoietic reconstitution potential of ssPBPC and mPBPC, following ex vivo manipulations, including cytokine exposure and retroviral gene transduction. Altogether, our results demonstrate that the CD34 ϩ cell populations isolated from peripheral blood, before and after mobilization with hematopoietic growth factors and/or chemotherapy, are different with regard to their phenotype, their ability to respond to cytokine stimulation, and the ability to maintain their hematopoietic reconstitution potential following ex vivo culture.
Methods

Cell collection and isolation of CD34
ϩ peripheral blood progenitors Apheresis samples and BM cells were obtained from patients (n = 20) and healthy donors (n = 3) after informed consent. Mobilized blood cell samples were obtained from cancer patients and normal volunteers at Institut Paoli-Calmettes. Cancer patients were treated with recombinant human (rh) granulocyte colony-stimulating factor (G-CSF, Filgrastim; Amgen, Thousand Oaks, CA, USA or Lenograstim; RhonePoulenc-Rorer, Neuilly-sur-Seine, France) alone (n = 4), or following chemotherapy (n = 16), while healthy volunteers were treated with rhG-CSF alone. Steady-state peripheral blood cells were obtained from normal volunteers at various institutions: Cobe BCT, (n = 4), Centre Régional de Transfusion Sanguine (n = 11), and Institut Paoli-Calmettes (n = 4). Peripheral blood cell collection was performed on a Cobe-Spectra apheresis processor using the stem cell software CMN 4.7 (Cobe BCT, Lakewood, CO, USA). Marrow samples were obtained from healthy donors for allogeneic transplantation (n = 3). A CD34 ϩ cell enriched fraction was prepared from mobilized peripheral blood cells (mPB-CD34 
Antibodies
The following monoclonal antibodies (MoAbs) were used for flow cytometric analysis: fluorescein isothiocyanate (FITC)-conjugated MoAbs to CD3, CD4, CD5, CD7, CD8, CD10, CD14, CD15, CD19, CD34, CD71, HLA-DR, and phycoerythrin (PE)-conjugated MoAbs to CD33, CD34, CD38 were purchased from Becton Dickinson (San Jose, CA, USA). FITCconjugated MoAbs to CD1a, CD2, CD25, CD33, CD38, CD41, anti-Glycophorin A, and PE-conjugated MoAbs to CD25, CD117, CD135 were purchased from Immunotech (Marseille, France). FITC-conjugated anti-CD90, biotin-conjugated anti-CD114, PE-conjugated anti-CD123 and the neutralite-avidin reagent were purchased from Pharmingen (San Diego, CA, USA). Tricolor (TC)-conjugated MoAbs to CD3, CD4, and CD8 were purchased from Caltag (San Francisco, CA, USA). PE-conjugated MoAb DX17, recognizing the monomorphic MHC class I antigen (a gift from Dr L Lanier at DNAX), and FITC-conjugated MoAbs recognizing the MHC class I alloantigens (HLA-A2, HLA-A3 and HLA-B7) (obtained from the American Type Tissue Collection, Rockville, MD, USA) were used to determine the origin of human cells. Isotype-matched MoAbs were used as negative controls.
Flow cytometry
Cells were incubated at 4°C in the dark in a solution of phosphate-buffered saline (PBS) (BioWhittaker, BIBP, Verviers, Belgium) supplemented with 1% human albumin (LFB, Les Ullis, France), 0.5% human immunoglobulin (Sandoz, RueilMalmaison, France), 5 mm EDTA-Na 2 (BioWhittaker, Walkersville, MA, USA). Normal mouse serum (2%) (Sigma Chemical, St Louis, MO, USA) was further supplemented for the staining of cells recovered from SCID-hu mice to avoid non-specific staining. Propidium iodide (Sigma Chemical) was added at a concentration of 1 g/ml before analysis to stain dead cells. Analyses were carried out using a FACScan flow cytometer equiped with the CellQuest software (Becton Dickinson).
Ex vivo manipulations
Ex vivo manipulations were performed as previously described. 22 In brief, immunoselected CD34 ϩ cells were cultured for 2 days in RPMI-1640 (JRH Biosciences, Lenexa, KS, USA), supplemented with 10% fetal bovine serum (FBS; BioWhittaker), 1% l-glutamine, 1% penicillin-streptomycin (Gibco BRL, Grand Island, NY, USA), and the combination of cytokines described below; this first step was used to induce proliferation of progenitor cells, and thus favor the integration of the Moloney-derived retroviral vector. Cells were then transferred on to mitomycin (Sigma Chemical pre-treated A7.21, a Psi-Crip-derived packaging cell line producing the MFG-S nls-LacZ retroviral vector that encodes a modified version of the E. coli ␤-galactosidase gene (nls-LacZ). 54 Three 440 days after coculture, cells were harvested by vigorous flushing, and plated twice to remove adherent packaging cells. Cytokine combinations were: condition (C)1: rh interleukin (IL)-3, rhIL-6 (R&D Systems, Minneapolis, MN, USA), rh granulocyte-macrophage colony-stimulating factor (GM-CSF; PeproTech, Rocky Hill, NJ, USA) at 10 ng/ml each, and rh ckit ligand (KL; R&D Systems) at 100 ng/ml; C2: C1 combination plus recombinant mouse (rm) F1k2/Flt3 ligand (FL; 100 U/ml) produced at DNAX Research Institute. 55 Cells were cultured in the same cytokine conditions for 5 days. In order to assess the effect of the gene transduction procedures, CD34 ϩ cells were also cultured in the absence of the packaging cells in the same cytokine conditions (CЈ1 and CЈ2) for 5 days.
In some experiments, cells were harvested and cryopreserved at various time points: unmanipulated (day 0), after 2 days of cytokine stimulation (day 2), and after 5 days in culture in the presence or absence of the packaging cell line (day 5). Cells were then thawed and injected into SCID-hu mice.
In vitro hematopoietic progenitor assays
Methylcellulose colony assays were performed with Methocult 4230 (Stem Cell Technology, Vancouver, Canada), supplemented with rhIL-3, rhIL-6, rhGM-CSF, rhG-CSF (Amgen, Thousand Oaks, CA, USA) at 10 ng/ml each, rhKL (100 ng/ml), and rh erythropoietin (Epo; Boehringer Mannheim, Mannheim Germany) at 2 U/ml. Colonies formed in methylcellulose were enumerated on day 14 of cultures. The sum of colony forming-unit granulocyte-macrophage (CFU-GM), CFU-granulocyte (CFU-G), and CFU-macrophage (CFU-M) is presented as CFU-GM, and hemoglobinized colonies were scored as BFU-E. Double-layered agarose cultures supplemented with rhIL-3, rhIL-6, rhG-CSF, rhGM-CSF, rhKL (20 ng/ml each) and rmFL (100 U/ml) were used for the detection of high-proliferative potential (HPP) colony-forming cells (CFC), and low-proliferative potential (LPP)-CFC, as previously described. 22, 56 Colonies were enumerated on day 21. HPP-CFC were defined as progenitors giving rise to colonies у0.5 mm in diameter. LPP-CFC were defined as progenitors giving rise to colonies of у50 cells, but smaller than the colonies derived from HPP-CFC.
SCID-hu mouse reconstitution assays
C.B-17 scid/scid (SCID) mice transplanted with either human fetal thymus and liver, 52 or human fetal BM 53 (SCID-hu mice) were prepared as previously described. Mice were selected so that human tissue grafts and progenitor cells were mismatched for commonly distributed MHC class I alloantigens. Each individual experiment used a set of mice generated by the transplantation of tissues derived from a single donor. Mice received 250 cGy whole body ␥-irradiation, immediately followed by the injection of progenitor cells directly into grafts. SCID-hu mice were sacrificed at various time points after injection (2-8 weeks) to analyze reconstitution by injected progenitor cells. All procedures were approved at DNAX by the institutional animal care committee, and the committee for protection of human subjects.
Detection of the nls-LacZ gene expression
Expression of the nls-LacZ gene in human cells recovered from SCID-hu mice was examined with a standard X-gal assay, on colonies observed in methylcellulose or agarose, and on cytospins. 22, 54 Briefly, fixed cells were incubated with X-gal reaction solution at 37°C for 2 h for cytospin preparations, and for 12 h for colonies. Cytospin slides were prepared using 10 to 25 × 10 3 total cells extracted from injected BM or thymus grafts. X-gal developed cytospin slides were then lightly stained with hematoxylin.
Data presentation and statistical analysis
Unless otherwise stated, the data from multiple experiments were pooled and are presented as the mean Ϯ standard error of mean (s.e.m.). Comparisons were carried out with nonparametric Mann-Whitney analyses, using the Statview software (Abacus Concept, Berkeley, CA, USA) for Macintosh computers. Differences were considered statistically significant when P р 0.05.
Results
Phenotypic comparison of freshly isolated ssPB-CD34
ϩ and mPB-CD34 ϩ cells
Flow cytometric analysis of freshly isolated PBPC revealed that ssPB-CD34 ϩ cells contained a population of cells that was rarely detectable in the mPB-CD34 ϩ cell fraction. By scatter analysis, ssPB-CD34 ϩ cells were found to distribute in two subsets: a 'blastic' population (gate R1 in Figure 1 ), with intermediate forward light scatter (FSC) and orthogonal light scatter (SSC), and a 'lymphoid' population (gate R2 in Figure 1 (Figure 1c) , fell in the lymphoid gate (P = 0.0017). It was found that ssPB-CD34 ϩ cells distributed in the lymphoid and blastic gates in a manner very similar to that of CD34 ϩ cells isolated from normal BM (Figure 1d) .
Results of phenotypic analyses of CD34 ϩ PBPC are summarized in Figure 2 and Table 1 . Differences between ssPB-CD34 ϩ cells and mPB-CD34 ϩ cells were evident in the expression of lymphoid lineage-associated markers on CD34 ϩ cells. T cell-associated antigens (CD1a, 2, 3, 4, 5 and 7) were expressed in significant percentages of ssPB-CD34 ϩ cells, while virtually no CD34 ϩ cells co-expressed these antigens in mPBPC (Figure 2a ). Although cells co-expressing T cell markers were found both in the blastic and lymphoid subsets of ssPB-CD34 ϩ cells, cells in the lymphoid gate were more enriched for these cells (Figure 2b and c) . Percentages of cells co-expressing B cell markers (CD10 and CD19) were low in both ssPB-CD34 ϩ cells and mPB-CD34 ϩ cells, but there was a tendency for ssPB-CD34 ϩ cells containing higher percentages of CD34 ϩ cells co-expressing these markers. In contrast to CD34
ϩ cells expressing T cell markers, CD34 ϩ cells coexpressing B cell markers were exclusively detected in the lymphoid subpopulation, a characteristic also shared by BM CD34 ϩ cells (data not shown). Among the antigens that are differently expressed on early and late progenitors, including CD33, CD38, CD71, CD90 (Thy 1) and HLA-DR, a statisti-
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Figure 1
Scatter profiles of CD34 + cells isolated from various sources. The blood CD34 + cell enriched fraction isolated from a steady-state healthy volunteer (a), a cancer patient mobilized with rhG-CSF (b), a healthy volunteer mobilized with rhG-CSF (c), and the BM CD34 + cell enriched fraction from a healthy volunteer (d) are gated as shown in the histogram and analyzed for FSC and SSC profiles. The R1 and R2 gates represent the blastic and lymphoid gates respectively, and were used for the analysis presented in Figure 2. cally significant difference was observed only for CD71 expression. Higher percentages of ssPB-CD34 ϩ cells expressed CD71 as compared to mPB-CD34 ϩ cells, especially in cells in the blastic gate (P = 0.0143). Expression of cytokine receptors in CD34 ϩ cells was also investigated. Interestingly, it was found that the tyrosine kinase receptor Flt3 (CD135) expression was higher in ssPB-CD34 ϩ cells than mPB-CD34 ϩ cells, while G-CSF receptor (CD114) expression was lower in ssPB-CD34 ϩ cells than in mPB-CD34 ϩ cells. However, these differences were not statistically significant. Cells expressing high levels of the CD34 antigen and negative for lineage antigens and the CD38 antigen were detected in subsets of ssPB-
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Figure 2
Different phenotypic profiles of ssPBPBC (n = 12) and mPBPC CD34 + cells (n = 9). Results are diplayed for the: (a) total CD34 + cells, (b) blastic (R1) gated CD34 + cells (see Figure 1 ), (c) lymphoid (R2) gated CD34 + cells (see Figure 1 ). Statistically significant differences (P р 0.05) are indicated by asterisks.
CD34
ϩ as well as mPB-CD34 ϩ cell samples, with however significant variations in individual samples.
Ex vivo expansion capacity of ssPB-CD34
The levels of expansion in cellularity, CD34 ϩ cell number, and clonogenic progenitor cell numbers induced during 5 day culture were compared between ssPB-CD34 ϩ cells and mPB-CD34 ϩ cells. No statistically significant difference in total cell or CD34 ϩ cell expansion was found between cells cultured in the presence (C2) and the absence (C1) of FL, and results are thereafter presented for the two conditions. After 5 days in culture in the presence of the packaging cell line, significantly higher levels of expansion in cellularity were observed in ssPB-CD34 ϩ cells (4.4-fold), when compared to mPB-CD34 ϩ cells (2.0-fold; P = 0.0158). More importantly, higher levels of expansion in CD34 ϩ cell numbers were induced in ssPB-CD34 ϩ cells (5.5-fold), than mPB-CD34 ϩ cells (1.7-fold; P = 0.0252). Interestingly, these differences were not evident in cells that were cultured in the absence of packaging cell line.
Flow cytometric investigation on the phenotype of ex vivo manipulated PBPC failed to demonstrate any significant difference between cultured ssPB-CD34 ϩ cells and mPB-CD34 Frequencies of clonogenic progenitors were measured at various time points during ex vivo manipulation, on day 0, day 2 and day 5. Freshly isolated (day 0) mPB-CD34 ϩ cells contained CFU-GM, LPP-CFC and HPP-CFC at significantly higher frequencies than ssPB-CD34 ϩ cells (P = 0.0455, 0.0472 and 0.0339, respectively; Table 2 ). After 5 days of culture, no significant difference was found in the frequencies of clonogenic progenitors, except for CFU-GM: a significantly higher frequency in CFU-GM was still maintained in mPB-CD34 ϩ cells as compared to ssPB-CD34 ϩ cells (9088 Ϯ 5259 vs 2942 Ϯ 2708, P = 0.001). No significant difference in progenitor cell frequencies was found between cells cultured in the presence or absence of FL.
Consistently with absolute numbers of clonogenic progenitors that are reported above, differences between ssPB-CD34 ϩ cells and mPB-CD34 ϩ cells appeared when looking at fold expansions (Table 2) . Results obtained with cells cultured in the presence and absence of FL were pooled in this analysis, since again no statistically significant differences were observed. The absolute number of HPP-CFC in ssPB-CD34 ϩ cells expanded on average 4.1-fold on day 2, while that in mPB-CD34 ϩ cells expanded only 1.3-fold (P = 0.0641). The difference became more evident on day 5 as a 4.6-fold expansion of HPP-CFC was induced in ssPB-CD34 ϩ cells, whereas the numbers of HPP-CFC in mPB-CD34 ϩ cells were, on average, less than 50% of the initial numbers (P = 0.0252).
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Continued. 
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a Gate R1 as defined in Figure 1 . b Gate R2 as defined in Figure 1 . 
In vivo reconstitution potential of ex vivo manipulated ssPB-CD34 and mPB-CD34 cells
Hematopoietic reconstitution by CD34
ϩ PBPC cultured for 5 days was assessed by direct injection into human fetal BM implanted in SCID mice. The contribution of injected progenitor cells to hematopoiesis was evaluated by flow cytometry, based on the expression of MHC class I alloantigens ( Figure  3) . In all (14/14) BM samples injected with cultured ssPB-CD34 ϩ cells, varying degrees of chimerism were observed when analyzed at 4-6 weeks after injection (four independent experiments) ( ϩ progenitor cells (9/9: 2.4-17.0%).
The potential to reconstitute the T cell compartment was investigated using SCID mice transplanted with human fetal thymus, along with fetal liver, under the kidney capsule. Contribution of cultured ssPB-CD34 ϩ cells to T lymphopoiesis was also evaluated by flow cytometry, based on the expression of MHC class I alloantigens ( Figure 3 ). All of nine thymic grafts injected with cultured ssPB-CD34 ϩ cells showed reconstitution by donor-derived cells, when analyzed at 6-8 weeks post injection (7.4-97.7%) ( Table 4 ). The distribution of T cell subsets in donor-derived cells was similar to normal human thymus (data not shown), with 72-97% of CD4 ϩ /CD8 ϩ double positive cells in all thymic grafts: this indicates that the thymus was reconstituted by progenitor cells, and that we did not detect mature T cells that could have been present in the initial cell population. Direct X-gal staining was performed on cytospin slides prepared with cells recovered from the thymic grafts, and rare ␤-Gal ϩ cells were observed (р1/10 000). In contrast to results obtained with ssPB-CD34 ϩ cells, reconstitution of human BM in SCID-hu mice injected with cultured mPB-CD34 ϩ cells was observed only in a small proportion of animals (14/66, nine independent experiments), and at very low levels (р3.8%), when analyzed at 2-8 weeks after injection (Table 5 ). In BM samples that contained donorderived cells, reconstitution was restricted to the CD33 ϩ myeloid cell population. No donor-derived cells were detected in the CD19 ϩ B cell population, nor in the CD34 ϩ progenitor cell population. Furthermore, cultured mPB-CD34 ϩ cells failed to reconstitute human thymus grafts. T cells derived from cultured mPB-CD34 ϩ cells were detected in none of the 35 thymus grafts from five independent experiments analyzed at 6-8 weeks after injection. These results with mPB-CD34 ϩ cells isolated from cancer patients were reproduced in one experiment with mPB-CD34 ϩ cells isolated from a healthy volunteer donor (GT7; Table 5 ).
As a confirmation of the low contribution of donor-derived cells to human hematopoiesis, no ␤-gal cells were detected in mice injected with cultured cells. Following gene transduction, and before injection, these cells contained on average 14.8% X-gal-positive cells (range 0.36-55%), and 13.2% Xgal-positive CFUs (range 0-44%), a result similar to already published reports.
54,57,58
Time-dependent loss of in vivo reconstitution potential of mPB-CD34
ϩ cells
In order to investigate the effects of ex vivo manipulation procedures, the hematopoietic reconstitution potential of mPB-CD34 ϩ cells was investigated at different time points during a 5 day culture. Aliquots from each samples were frozen at day 0 after CD34 ϩ immunoselection ('unmanipulated'), after 2 days in culture, and after 5 days in culture in the absence or in the presence of packaging cells. Cryopreserved cells were then thawed and injected into a set of SCID-hu mice created with BM from a single donor. Human BM were analyzed at 4 weeks after injection. The results of two independent experiments clearly demonstrated that unmanipulated mPB-CD34 ϩ cells possessed the potential to reconstitute multiple cell lineages (Figure 4) . All of the BM samples showed varying degrees of chimerism by donor-derived and BM host-derived cells. Donor-derived cells were detected in both CD19
ϩ B cells (12.9-46.2%) and CD33 ϩ myeloid cells (2.3-73.7%) in these BM samples. Cells harvested on day 2 still maintained the potential to reconstitute both CD19 ϩ (1.0-7.7%) and CD33 ϩ (40.6-72.2%) cell populations. However, the levels of B cell reconstitution achieved by these cells were significantly lower than those achieved by unmanipulated day 0 cells. The loss of the reconstitution potential of mPB-CD34 ϩ cells became evident after 5 days in culture. Contribution of injected mPB-CD34 ϩ cells to hematopoietic recovery dropped to 0.2-7.7%, and more significantly, their contribution to B cell reconstitution dropped to 0-1.5%. In contrast, appreciable numbers of CD33 ϩ cells were derived from the injected mPB-CD34 ϩ cells (1.4-46.2%), although the levels of reconstitution achieved by these cells were also lower than those achieved by cells harvested on day 0 or day 2. No significant difference was found between mPB-CD34 ϩ cells cultured for 5 days in the presence or absence of FL, or the presence or absence of the packaging cell line.
The percentages of CD34 ϩ cells in the injected cells dropped from Ͼ90% at day 0, to 70-80% at day 2, and to 50% at day 5. However, it is important to note that the percentages of CD34 ϩ cells in mPB-CD34 ϩ cells cultured for 5 days were comparable to those of ssPB-CD34 ϩ cells cultured for 5 days (Tables 3, 4 
Discussion
A number of pre-clinical models, 40, 41, 59, 60 and human allogeneic transplantation [7] [8] [9] [10] have demonstrated the presence of stem cells with long-term marrow repopulating ability in the peripheral blood of mobilized cancer patients or healthy donors. However, in contrast to the advantages of autologous mPBPC, such as the ease of collection and early hematopoietic recovery, results obtained with ex vivo manipulated CD34 ϩ mPBPC were disappointing, both for ex vivo expansion, 26 or gene transfer. 17, 18 Although the low level of reconstitution by gene modified mPBPC may be attributed to a number of factors, including the nature of retroviral vectors, the observation that progenitor cells obtained from fetal tissues or from cord blood support better results, suggests that the source of progenitor cells is of critical importance for the development of successful gene transfer protocols. mPBPC may be unique, as they are obtained from an individual whose homeostasis has been disturbed by chemotherapy and/or the administration of a hematopoietic growth factor, usually rhG-CSF. Therefore, the biological properties of mPBPC may in part reflect the fact that they were exposed in vivo to pharmacological levels of hematopoietic growth factors.
The present study was conducted to investigate the biologi- 
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؉ PBPC L Humeau et al 447 cal properties of steady-state and mobilized peripheral blood CD34 ϩ progenitors, using both freshly isolated cells and cells cultured under various conditions for gene transduction. The functions of these cells were evaluated by in vitro assays and with the SCID-hu mouse models. Direct comparison between ssPB-CD34 ϩ cells and mPB-CD34 ϩ cells revealed significant differences in both phenotype and function of these progenitor populations.
The most striking difference observed in the present study is the primitive progenitor activity contained in the CD34 ϩ population of adult peripheral blood. In vitro studies demonstrated that progenitor cell activities found in freshly isolated ssPB-CD34 ϩ cells and mPB-CD34 ϩ cells were different. The frequencies of CFU-GM, LPP-CFC and HPP-CFC contained in the freshly isolated mPB-CD34 ϩ cells were significantly higher than those in ssPB-CD34 ϩ cells. However, after 5 day culture in the presence of the packaging cells, ssPB-CD34 ϩ cells proliferated to a greater extent than mPB-CD34 ϩ cells. Signifi- cantly higher levels of expansion in both cellularity and in the number of CD34 ϩ cells were achieved by ssPB-CD34 ϩ cells. Furthermore, a significant difference was found in the levels of expansion of early progenitors identified as HPP-CFC. Absolute numbers of HPP-CFC increased 4.6-fold in ssPB-CD34 ϩ cells after 5 day culture, whereas those in mPB-CD34 ϩ cells were less than the initial numbers, despite the fact that a higher frequency of HPP-CFC was found in the initial mPB-CD34 ϩ cell population. These results suggest that ssPB CD34 ϩ cells contain higher numbers of pre-HPP-CFC, or that primitive progenitors present in mPBPC possess a lower expansion potential.
In accordance with results obtained in in vitro studies, a significant difference was demonstrated in the potential to reconstitute human hematopoiesis in SCID-hu mice, following ex vivo manipulation. Cultured ssPB-CD34 ϩ cells were shown to retain the ability to reconstitute CD19 ϩ B cells, CD33 ϩ myeloid cells and CD34 ϩ progenitor cells in the marrow, as well as T cells in the thymus after 5 days in culture. In contrast, cultured mPB-CD34 ϩ cells failed to reconstitute B cells in the marrow and T cells in the thymus. BM samples were analyzed as early as 2 weeks after injection, in order to exclude the possibility of early, yet transient, reconstitution by manipulated mPB-CD34 ϩ cells. Further investigation revealed that the reconstitution potential of mPB-CD34 ϩ cells decreased as a function of time during the culture and ex vivo exposure to cytokine combinations. Thus, the multilineage reconstitution potential observed in the freshly isolated mPB-CD34 ϩ cells was almost completely lost by day 5 of culture. The B cell reconstitution potential dramatically dropped after 2 days in culture, and was almost completely abolished after 5 days in culture. The myeloid reconstitution potential was preserved at lower levels than with freshly isolated mPB-CD34 ϩ cells. It is unlikely that gene transduction is responsible for the loss of the reconstitution potential, because cells cultured in the absence of the retroviral vector producing cell line failed to reconstitute hematopoiesis. These results suggest that cultured mPB-CD34 ϩ cells contain mostly myeloid committed progenitors, whereas cultured ssPB-CD34 ϩ cells still contain both myeloid committed and lymphoid committed progenitors, and/or uncommitted progenitors in sufficient numbers to reconstitute human hematopoiesis in SCID-hu mice. Cytokine combinations used in the study may influence the maintenance of myeloid reconstitution potential and the loss of B cell reconstitution potential. In our hands, the addition of FL in the culture did not induce any significant difference in maintaining the B cell reconstitution potential, although FL has been reported to support the maintenance of the primitive progenitor activity and the proliferation of B cell progenitors. 
Our observations that mPB-CD34
ϩ cells have lower in vitro proliferative potential, do not expand HPP-CFC in vitro, and lose in vivo reconstitution potential during ex vivo cultures, indicate that CD34 ϩ cells that are mobilized either with rhG-CSF or with chemotherapy, and collected either from cancer patients or from healthy volunteers, possess different biological properties from those of ssPB CD34 ϩ cells. This, together with the relatively low efficiency of Moloney-derived retroviral vectors to target and integrate into human early hematopoietic progenitors, may in part explain results of recent clinical studies, demonstrating that gene modified mPB CD34 ϩ progenitors contribute only modestly to hematopoietic recovery, following retroviral infection in the presence or absence of exogenous cytokines, or during coculture with stromal cells. 17, 26 This is also consistent with recently published results in non human primates: 34 although cultures were carried out for longer periods of time, these observations suggest that ex vivo exposure of mobilized and genetically marked Rhesus peripheral blood cells to SCF, IL3 and IL6 is detrimental to their ability to reconstitute hematopoiesis in myeloablated recipients, and that addition of FL only partially prevent these alterations.
Flow cytometric studies with freshly isolated cells also demonstrated differences between ssPB-CD34 ϩ cells and mPB-CD34 ϩ cells. ssPB-CD34 ϩ cells contained significant percentages of cells falling in the 'lymphoid' electronic gate defined by a low FSC and a low SSC, while mPB-CD34 ϩ cells virtually lacked this population. This difference was associated with the absence or very low percentages of CD34 ϩ cells that coexpress T lineage markers (CD 1a, 2, 3, 4, 5 and 7) in mPB-CD34 ϩ cells. The presence of CD34 ϩ cells that co-express T cell-associated markers in ssPBPC 45, 46 and the absence of this subset of CD34 ϩ cells in mPBPC 38, 62, 63 have already been reported. The present study confirms these earlier observations by directly comparing ssPB-CD34 ϩ cells and mPB-CD34 ϩ cells. This subset of CD34 ϩ cells may represent a population of T cell precursors circulating in blood; however, the paucity of CD34 ϩ PBPC that were recovered from steady-state aphereses did not allow us to investigate further their ability to differentiate towards T cells, either in the SCID-hu model or in the fetal thymic organ culture system. 64 Nonetheless, it is unlikely that the lack of this population is responsible for the observed loss of T cell reconstitution potential in mPB-CD34 ϩ cells following ex vivo manipulation. Previous studies demonstrated that human thymic grafts in the SCID-hu mouse can be reconstituted by uncommitted progenitors such as unmanipulated CD34 ϩ /Lin Ϫ cells isolated from mPBPC 41 or from fetal liver, 65 two cell populations that do not contain T cell antigen expressing cells.
Altogether, our results suggest that the mPB-CD34 ϩ cell population is enriched for the more differentiated myeloid progenitors. The observation that freshly isolated mPB-CD34 ϩ cells contained clonogenic progenitor cells at higher frequencies than ssPB-CD34 ϩ cells further supports this possibility. Regardless of the regimen, mobilization induces the egress out of the marrow of the most differentiated progenitor cells from the marrow, 66 cells which fall in the blastic gate in flow cytometric analysis of enriched CD34 ϩ cells. As a consequence, more primitive progenitors can be diluted by more mature cells. In addition, in vivo exposure to a hematopoietic growth factor prior to ex vivo manipulations, may induce changes in biological properties of early progenitor cells. Further studies are required to elucidate whether the observed functional differences reflect qualitative or quantitative differences of primitive progenitor cells present in the CD34 ϩ cell populations, before and after mobilization.
The substitution of autologous mobilized blood cells to BM cells has greatly contributed to the development of high-dose chemotherapy for the treatment of cancer patients. However, together with results reported by other groups, 17, 18, 26 our observations question the hypothesis that mPBPC are an optimal population for stem cell-based cell or gene therapy, at least with culture conditions that we and other groups have used; it remains, however, possible that the long-term marrow repopulating ability of these cells can be better maintained with improved culture conditions, including other cytokine combinations, or the substitution of serum-free to serumreplete medium. The use of ssPBPC does not appear to be a feasible alternative in clinical practice, 67 due to the extremely low numbers of these cells. The comparison of mPBPC with ssPBPC, however, underlines the importance of understanding the biological properties of progenitor cells, that differ depending on the chronology in ontogeny, anatomical locations, and the collection conditions, including mobilization. Further studies to identify the optimal target cells for cell and gene therapies are required in order to improve the hematopoietic reconstitution efficiency by cultured and/or genetically modified cells, thereby providing clinical benefits with these approaches.
